BioNTech Expands Global Collaborations through Licensing Agreements

Introduction:

On November 6th, Pumis Biotechnology announced a licensing and collaboration agreement with BioNTech regarding the development of their independently developed anti-PD-L1/VEGF bispecific antibody, PM8002. Under the terms of the agreement, Pumis will gain the rights for development, manufacturing, and commercialization of PM8002 globally (excluding Greater China), and in return, they will receive an upfront payment of $55 million, as well as over $1 billion in development, regulatory, and commercial milestone payments, along with tiered sales royalties.

PM8002: A Promising Bispecific Antibody Candidate
PM8002 is a bispecific antibody candidate composed of a humanized anti-PD-L1 single-domain antibody (VHH) fused to an anti-VEGF-AIgG1 antibody containing an Fc-silencing mutation. By enriching PM8002 molecules in the tumor microenvironment through PD-L1, it aims to reduce systemic side effects caused by the systemic blockade of VEGF. Currently, PM8002 is undergoing Phase II clinical trials in China, evaluating its efficacy and safety as a monotherapy or in combination with chemotherapy in patients with solid tumors. Existing clinical results have shown that PM8002 has good safety and promising anti-tumor efficacy. The latest research data has been presented at the ASCO 2023 and ESMO 2023 conferences, with further data expected to be published at important international oncology conferences.

BioNTech's Expansion in China and Collaborations with Domestic Biotech Companies:
The collaboration between BioNTech and Pumis marks their second partnership following their initial collaboration in July. This renewed partnership has garnered attention as it signifies another product transfer to a domestic biotech company in China. Moreover, it refocuses attention on BioNTech as a company that has sparked a buying frenzy in the country.

According to statistics, this license-in agreement is BioNTech's seventh collaboration with Chinese companies this year. Earlier in the year, BioNTech entered into a global exclusive license and collaboration agreement with OncoC4 for the development and commercialization of ONC-392, a next-generation anti-CTLA-4 monoclonal antibody candidate for various cancer indications, with an upfront payment and potential milestone sales sharing of up to $200 million. Additionally, BioNTech signed agreements with Yingrun Biopharma and acquired their three ADC candidates, and partnered with Daorui Biotech for the development of innovative biologic therapies targeting an undisclosed target.

BioNTech's Strategic Shift and Licensing Agreements:
BioNTech's recent collaborations and licensing agreements with Chinese biotech companies are part of its strategic shift to mitigate the decline in revenue from COVID-19-related products. The company's third-quarter financial results for 2023 showed a decrease in revenue by 74% compared to the same period last year, resulting in a decline of over 35% in its stock price. The majority of BioNTech's revenue relies on profit sharing with Pfizer.

By partnering with Chinese companies and licensing their investigational products, BioNTech aims to supplement its product pipeline, achieve a transformation in the post-pandemic era, and diversify its revenue streams. These collaborations not only demonstrate the strength of the domestic biopharmaceutical sector but also highlight the global interest in Chinese biotech companies' research and development capabilities.

Conclusion:
BioNTech's licensing agreements and collaborations with Chinese biotech companies, including the recent partnership with Pumis Biotechnology, signify the company's strategic efforts to expand its global presence and product portfolio. These alliances enable BioNTech to tap into promising investigational drugs while providing domestic biotech companies in China with opportunities for product transfer and global exposure. As the world transitions into a post-pandemic era, such collaborations demonstrate the growing importance of international partnerships in advancing biopharmaceutical innovation and addressing global healthcare challenges.